Koray YALÇIN, Gülen TÜYSÜZ KİNTRUP, Funda Tayfun KUPESİZ, Alphan KÜPESİZ, Elif GÜLER, Selen BOZKURT

Can peripheral blood monocyte percentage and lymphocyte monocyte ratio at diagnosis predict survival in pediatric neuroblastoma patients?

Background. Previous studies have shown that the immune system plays a critical role in cancer pathogenesis. The lymphocyte monocyte ratio (LMR) and monocyte percentage (MP) have been found to be prognostic factors in various types of adult cancers. But studies about pediatric tumors are scarce and to our knowledge, there are no studies evaluating the immune system effect in pediatric neuroblastoma patients. The aim of this study was to assess whether LMR and MP at diagnosis may have an effect on prognosis in neuroblastoma patients. Methods. We retrospectively analyzed MP and LMR at diagnosis in 71 pediatric neuroblastoma patients treated between 2002 and 2016. Results. The optimal cut-off values of LMR and MP were determined using the receiver operating characteristics curves (ROC) and area under the curve (AUC). We found that a low LMR (≤3.5) and a high MP (≥7.5%) were correlated with worse overall survival and shorter event-free survival in univariate analysis. Multivariate analysis revealed that elevated LMR was an independent factor for better OS and EFS. Conclusions. In conclusion, LMR and MP might be valuable prognostic factors for predicting OS in neuroblastoma patients. Multicenter and prospective studies are warranted to confirm this hypothesis.

PDF

___

1. Tredan O, Manuel M, Clapisson G, et al. Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. Eur J Cancer 2013; 49: 1673-1682.

2. Liang L, Zhu J, Jia H, et al. Predictive value of pretreatment lymphocyte count in stage II colorectal cancer and in high-risk patients treated with adjuvant chemotherapy. Oncotarget 2016; 7: 1014- 1028.

3. Milne K, Alexander C, Webb JR, et al. Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. J Transl Med 2012; 10: 33.

4. Mehrazin R, Uzzo RG, Kutikov A, et al. Lymphopenia is an independent predictor of inferior outcome in papillary renal cell carcinoma. Urol Oncol 2015; 33: 388.e19-388.e.25.

5. Jinushi M, Komohara Y. Tumor-associated macrophages as an emerging target against tumors: creating a new path from bench to bedside. Biochim Biophys Acta 2015; 1855: 123-130.

6. Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica 2012; 97: 262-269.

7. Li ZM, Huang JJ, Xia Y, et al. Blood lymphocyte-tomonocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One 2012; 7: e41658.

8. Colon NC, Chung DH. Neuroblastoma. Adv Pediatr 2011; 58: 297–311.

9. Birch JM, Blair V. The epidemiology of infant cancers. Br J Cancer Suppl 1992; 18: S2-S4.

10. Irwin MS, Park JR. Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am 2015; 62: 225-256.

11. Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998; 16: 1265-1269.

12. Cole WH, Everson TC. Spontaneous regression of cancer: preliminary report. Ann Surg 1956; 144: 366- 383.

13. Papac RJ. Spontaneous regression of cancer: possible mechanisms. In Vivo 1998; 12: 571-578.

14. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.

15. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature 2008; 454: 436-444.

16. Chan JC, Chan DL, Diakos CI, et al. The lymphocyteto-monocyte ratio is a superior predictor of overall survival in comparison to established biomarkers of resectable colorectal cancer. Ann Surg 2017; 265: 539-546.

17. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002; 8: 2553-2562.

18. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148.

19. Li J, Jiang R, Liu WS, et al. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma PLoS One 2013; 8: e83069.

20. Huang Y, Feng JF. Low preoperative lymphocyte to monocyte ratio predicts poor cancer-specific survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther 2015; 8: 137-145.

21. Hsu JT, Wang CC, Le PH, et al. Lymphocyte-tomonocyte ratios predict gastric cancer surgical outcomes. J Surg Res 2016; 202: 284-290.

22. Qi Q, Geng Y, Sun M, Wang P, Chen Z. Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer. Pancreatology 2015; 15: 145-150.

23. Neal CP, Cairns V, Jones MJ, et al. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases. Med Oncol 2015; 32: 144.

24. Deng YX, Lin JZ, Peng JH, et al. Lymphocyteto-monocyte ratio before chemoradiotherapy represents a prognostic predictor for locally advanced rectal cancer. Onco Targets Ther 2017; 10: 5575-5583.

25. Wang Y, Huang D, Xu WY, Wang YW, Che GW. Prognostic value of pretreatment lymphocyte-tomonocyte ratio in non-small cell lung cancer: a metaanalysis. Oncol Res Treat 2019; 42: 523-531.

26. Lu C, Zhou L, Ouyang J, Yang H. Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis. Medicine (Baltimore) 2019; 98: e15876.

27. Koh YW, Shin SJ, Park C, Yoon DH, Suh C, Huh J. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumourassociated macrophages. Hematol Oncol 2014; 32: 178-186.

28. Mantovani A, Sica A, Locati M. New vistas on macrophage differentiation and activation. Eur J Immunol 2007; 37: 14-16.

29. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015; 15: 73-86.

30. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.

31. Allavena P, Sica A, Garlanda C, Mantovani A. The yin-yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008; 222: 155-161.

32. Raj SKS, Kooshki M, Winters M, et al. Prognostic implications of tumor associated macrophages (TAMs) in soft tissue sarcoma. J Clin Oncol 2019; 37(Suppl 15): e22548.

33. Schmidt H, Bastholt L, Geertsen P, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005; 93: 273-278.

34. Asgharzadeh S, Salo JA, Ji L, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol 2012; 30: 3525-3532.